Skip to search formSkip to main contentSkip to account menu

Response Evaluation Criteria in Cancer of the Liver

Known as: RECICL 
Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). (Kudo M, Kubo… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Hepatocellular carcinoma (HCC), cholangiocarcinoma, and pancreatic ductal adenocarcinoma (PDAC) are the most common primary… 
Review
2017
Review
2017
Sorafenib has been the only approved systemic therapy for hepatocellular carcinoma until very recently. However, the radiologic… 
2015
2015
Objectives: Sorafenib has become a standard therapy for advanced hepatocellular carcinoma following the demonstration of… 
2013
2013
AIM To evaluate the therapeutic efficacy of transcatheter arterial chemoembolization (TACE) using miriplatin emulsion in… 
2011
2011
RECIST, mRECIST and RECICL are criteria for evaluating the therapeutic response of hepatocellular carcinoma and there are several… 
2010
2010
1.はじめに 「肝癌治療直接効果判定基準」 (Response Evaluation Criteria in Cancer of the Liver:RECICL)は,1993 年 10月に第 1版が作成され,1994… 
2005
2005
In the modern World, there is a growing trend to use unconventional construction materials, in order to look for solutions to…